Tirzepatide.
Mounjaro · Zepbound · compounded
Dual GIP + GLP-1 receptor agonist made by Eli Lilly. Higher weight-loss ceiling than semaglutide in head-to-head trials, more constrained supply globally, and pricing that varies by an order of magnitude across regions.
NHS (diabetes only, rare). Prescription charge if NHS covers for T2D. Weight-only prescriptions are virtually never covered.
See all regions ranked →Mechanism + ceiling
Activates both the GIP and GLP-1 receptors. The dual mechanism is what drives the larger weight-loss effect compared to GLP-1-only agonists; GIP appears to amplify GLP-1 signaling on appetite + glucose handling, though the exact contribution is still being characterised.
SURMOUNT-1 reported up to 22.5% mean body-weight reduction at 15 mg over 72 weeks. Real-world results trend lower because dose titration is often not pushed to the SURMOUNT protocol max.
Approved for type-2 diabetes (Mounjaro) and chronic weight management (Zepbound) in the US, EU, UK, Japan, and most major markets. Approval is faster than supply in many markets — local pharmacies often cannot fill the prescription.
17 regions, sorted cheapest first
Each region links to its full breakdown — pricing bands, vendor channels, legal routes, supply state, practical notes for travelers and residents.
Where to next
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.